Related Experiment Video
Updated: Jun 6, 2026

Direct Drug Delivery to Kidney via the Renal Artery
Published on: April 17, 2021
The kidney as a target organ in pharmaceutical research
Marco Prunotto1, Giulio Gabbiani, Silvia Pomposiello
1Institute of Clinical Pathology, University Hospital Geneva, Geneva 1211, Switzerland. marco.prunotto@gmail.com
Abstract:
Kidney diseases are a major source of morbidity and mortality in humans. In developed countries, mortality owing to chronic kidney disease (CKD) terminating in end-stage renal failure is comparable with that associated with cancer. A full understanding of the mechanisms implicated in the progression of CKD is needed to achieve its prevention and to delay the need for support strategies based on dialysis and transplantation. Renal fibrosis is the unifying feature of progressive renal alterations. In this review, we discuss the current status of possible mechanisms, tools and targets in CKD. Pathophysiological compound identification, biomarker discovery and accurate selection of clinical validation criteria appear to be three key elements needed to develop a successful innovative pharmaceutical approach to treating kidney diseases.
Insights
Chronic kidney disease (CKD) is a significant cause of death. Understanding renal fibrosis mechanisms is crucial for developing new pharmaceutical treatments to prevent disease progression and reduce the need for dialysis.
Area of Science:
- Nephrology
- Pathophysiology
- Pharmacology
Background:
- Kidney diseases contribute significantly to human morbidity and mortality.
- Chronic kidney disease (CKD) mortality rivals cancer mortality in developed nations.
- Renal fibrosis is a common pathway in progressive kidney damage.
Purpose of the Study:
- To review current knowledge on mechanisms, tools, and targets for treating CKD.
- To highlight the importance of understanding CKD progression.
- To identify key elements for innovative pharmaceutical approaches.
Main Methods:
- Literature review of mechanisms, tools, and targets in CKD.
- Discussion of pathophysiological compound identification.
- Analysis of biomarker discovery and clinical validation criteria.
Main Results:
- Renal fibrosis is a central feature of progressive kidney disease.
- Understanding CKD mechanisms is vital for prevention and delaying renal failure.
- Pharmaceutical development requires focus on specific targets and validation.
Conclusions:
- Effective CKD treatment strategies require a comprehensive understanding of disease mechanisms.
- Innovative pharmaceutical approaches depend on identifying key pathophysiological compounds and biomarkers.
- Rigorous clinical validation is essential for successful drug development in nephrology.
Related Concept Videos
Drug Elimination by Renal Route: Glomerular Filtration
Renal Drug Excretion: Overview
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules out...
Renal Drug Excretion: Glomerular Filtration
Drugs gain access to the kidney via the renal artery, which progressively branches off into afferent arterioles.
Drug Elimination by Renal Route: Tubular Secretion
Kidney Transplant I: Introduction
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

